SB 5353
In CommitteeSenate
Diabetes and obesity
Concerning the diabetes prevention and obesity treatment act.
This status may be delayed. See Action History below for the latest updates.
How does a bill become law?
- Introduced: The bill is filed and assigned a number.
- Committee: A subject-matter committee holds hearings, takes public testimony, and decides whether to advance the bill.
- Floor Vote: The full chamber (House or Senate) debates and votes on the bill.
- Opposite Chamber: The bill repeats the committee and floor vote process in the other chamber.
- Governor: The Governor reviews the bill and decides whether to sign or veto it.
- Signed: The bill has been signed into law.
AI Analysis
This bill treats obesity as a chronic disease and requires private health insurers and Medicaid to cover FDA-approved treatments—including behavioral therapy, medications, and surgery—without stricter rules than other medical conditions. It also sets a November 2025 deadline for Medicaid to apply for federal funding to support these benefits.
- Starting January 1, 2026, private health insurers must cover diagnosis and treatment of obesity, including intensive behavioral/lifestyle programs, FDA-approved weight-loss medications, and metabolic/bariatric surgery.
- Coverage for obesity treatments cannot be more restrictive than coverage for other medical conditions—same deductibles, copays, and annual limits must apply.
- Health plans may use utilization management (e.g., prior authorization) for obesity treatments, but only if applied the same way as for other conditions.
- Medicaid (including managed care plans) must cover obesity treatments after securing federal approval for matching funds by November 1, 2025.
- Intensive behavioral treatment must be evidence-based and may include CDC-certified or clinically recommended programs, delivered in person or via telemedicine.
Who is affected
- People with obesity or weight-related health concerns — Residents with obesity or at risk for obesity who have health insurance through private insurers, state-offered health plans, or Medicaid-managed care will gain access to covered treatments for obesity as a chronic disease.
- Private health insurance companies — Private health insurers and health carriers must cover obesity-related services and cannot apply stricter rules than for other medical conditions.
- Medicaid recipients — Medicaid beneficiaries in Washington will gain access to obesity treatments after the state secures federal funding approval.
- State employees and participants in state health plans — State employees and participants in state-offered health plans will be covered under the same obesity treatment requirements as other state health plans.
Pro/Con Analysis
Stronger case for benefits
Potential Benefits (5)
People with obesity—especially low-income, Medicaid-enrolled, or underinsured individuals—will gain access to evidence-based, FDA-approved treatments (e.g., GLP-1 medications, bariatric surgery) that are currently often excluded or subject to high cost-sharing, reducing barriers to care and potentially improving long-term health outcomes.
HealthcarePeopleRef: Sec. 1(1); Sec. 3(2)By requiring that obesity coverage not be more restrictive than other medical conditions (e.g., same deductibles, copays, annual limits), the bill helps prevent discriminatory cost-sharing practices that have historically made obesity treatment financially inaccessible to everyday Washingtonians.
HealthcarePeopleRef: Sec. 1(3); Sec. 3(4)The inclusion of CDC-certified or clinically recommended intensive behavioral programs—delivered via telemedicine—expands access to preventive, non-surgical interventions, supporting health literacy and self-management skills, especially for people in rural or transit-limited areas.
EducationPeopleRef: Sec. 1(5); Sec. 3(5)The state’s application for federal Medicaid matching funds by November 2025 could generate significant federal dollars (estimated 65–78% federal match) to offset state costs, potentially reducing the net fiscal burden on state and local budgets while expanding coverage.
FinancialLean peopleRef: Sec. 3(1)By treating obesity as a chronic disease requiring standard medical coverage, the bill may reduce long-term emergency and acute care utilization linked to obesity-related complications (e.g., diabetes, cardiovascular events), improving population health and easing strain on emergency services.
Public SafetyPeopleRef: Sec. 1(1); Sec. 3(2)
Potential Concerns (5)
The bill may increase premiums and out-of-pocket costs for many Washingtonians, as insurers and Medicaid must cover obesity treatments without stricter cost-sharing rules—potentially raising overall health plan costs without offsetting revenue or cost-control mechanisms.
FinancialRef: Sec. 1(3); Sec. 3(4)While utilization management (e.g., prior authorization) is permitted, the requirement that it be applied identically to obesity as to other conditions may delay or limit access for low-income or medically underserved patients who lack resources to navigate prior authorization hurdles—especially for time-sensitive interventions like weight-loss medications.
Public SafetyRef: Sec. 1(4); Sec. 3(4)The prohibition on more restrictive coverage criteria for FDA-approved obesity medications may conflict with clinical judgment—for example, if a medication is FDA-approved for weight loss but not yet supported by robust evidence for long-term safety or efficacy in specific populations (e.g., adolescents, people with comorbidities), potentially leading to inappropriate or ineffective treatment.
HealthcareRef: Sec. 1(2); Sec. 3(3)The bill allows CDC-certified or clinically recommended behavioral programs, but does not mandate provider qualifications or program quality oversight—risking inconsistent or low-quality care, especially in rural or underserved areas where certified programs may be scarce.
HealthcareRef: Sec. 1(5); Sec. 3(5)The bill imposes new coverage mandates on private insurers and Medicaid without specifying state funding to support implementation—potentially straining local public health departments and community clinics that serve as safety-net providers for obesity treatment, especially in counties with limited infrastructure.
Local GovernmentRef: Sec. 1(1); Sec. 3(1)
Who Is Most Affected
Low- and middle-income Washingtonians with obesity—especially those on Medicaid or purchasing individual plans—will benefit most, gaining access to previously excluded or cost-prohibitive treatments. However, those without insurance or in narrow-network plans may still face access barriers despite coverage mandates.
Private insurers will face new coverage mandates but may offset costs through risk adjustment and federal risk corridors; however, small-group and individual market carriers may face disproportionate administrative burdens due to limited scale and bargaining power.
Medicaid managed care organizations will receive federal matching funds but must expand benefits without guaranteed rate increases—potentially squeezing margins, while providers in MCO networks may see increased patient volume and reimbursement for obesity services.
Pharmaceutical manufacturers of FDA-approved weight-loss medications (e.g., GLP-1 agonists) stand to gain significant new market access, while CDC-certified behavioral health program providers may see increased demand and reimbursement—though rural or community-based providers may lack capacity to scale quickly.
State employees and participants in state health plans (e.g., LEOFF, PEBHS) will receive the same coverage as other state plans, but the lack of explicit funding or implementation guidance may delay rollout or cause inconsistent application across plan types.